Cdc42 deficiency induces podocyte apoptosis by inhibiting the Nwasp/stress fibers/YAP pathway

Cell Death and Disease

Volumn 7, Issue 3, 2016, Pages

  Huang, Z ^a,b   Zhang, L ^b   Chen, Y ^b   Zhang, H ^b   Zhang, Q ^b   Li, R ^b   Ma, J ^b   Li, Z ^b   Yu, C ^b   Lai, Y ^b   Lin, T ^b   Zhao, X ^b   Zhang, B ^b   Ye, Z ^b   Liu, S ^b   Wang, W ^b   Liang, X ^b   Liao, R ^b   Shi, W ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLUCOSE; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN CDC42; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; NEURAL WISKOTT ALDRICH SYNDROME PROTEIN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR; WASL PROTEIN, HUMAN; YAP1 PROTEIN, HUMAN;

ACTIN POLYMERIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; APOPTOSIS RATE; ARTICLE; CDC42 DEFICIENCY; CELL DIFFERENTIATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STRESS FIBER; WESTERN BLOTTING; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CDC42 GTP-BINDING PROTEIN; HUMANS; PHOSPHOPROTEINS; PODOCYTES; PROTEINURIA; SIGNAL TRANSDUCTION; STRESS FIBERS; TRANSCRIPTION FACTORS; WISKOTT-ALDRICH SYNDROME PROTEIN, NEURONAL;

EID: 85010630120     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.51     Document Type: Article

References (47)

1. Canaud G, Bienaime F, Viau A, Treins C, Baron W, Nguyen C et al. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med 2013; 19: 1288–1296.
2. Li R, Zhang L, Shi W, Zhang B, Liang X, Liu S et al. NFAT2 mediates high glucose-induced glomerular podocyte apoptosis through increased Bax expression. Exp Cell Res 2013; 319: 992–1000.
3. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225–233.
4. Marshall CB, Krofft RD, Pippin JW, Shankland SJ. CDK inhibitor p21 is prosurvival in adriamycin-induced podocyte injury, in vitro and in vivo. Am J Physiol Renal Physiol 2010; 298: F1140–F1151.
5. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420: 629–635.
6. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005; 21: 247–269.
7. Mouawad F, Tsui H, Takano T. Role of Rho-GTPases and their regulatory proteins in glomerular podocyte function. Can J Physiol Pharmacol 2013; 91: 773–782.
8. Reiser J, Sever S. Podocyte biology and pathogenesis of kidney disease. Annu Rev Med 2013; 64: 357–366.
9. Wang L, Ellis MJ, Gomez JA, Eisner W, Fennell W, Howell DN et al. Mechanisms of the proteinuria induced by Rho GTPases. Kidney Int 2012; 81: 1075–1085.
10. Meyer-Schwesinger C, Dehde S, Sachs M, Mathey S, Arefi K, Gatzemeier S et al. Rho-kinase inhibition prevents proteinuria in immune-complex-mediated antipodocyte nephritis. Am J Physiol Renal Physiol 2012; 303: F1015–F1025.
11. Scott RP, Hawley SP, Ruston J, Du J, Brakebusch C, Jones N et al. Podocyte-specific loss of Cdc42 leads to congenital nephropathy. J Am Soc Nephrol 2012; 23: 1149–1154.
12. Blattner SM, Hodgin JB, Nishio M, Wylie SA, Saha J, Soofi AA et al. Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injury. Kidney Int 2013; 84: 920–930.
13. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19: 491–505.
14. Huang J, Wu S, Barrera J, Matthews K, Pan D. The hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 2005; 122: 421–434.
15. Cao X, Pfaff SL, Gage FH. YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes Dev 2008; 22: 3320–3334.
16. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008; 283: 5496–5509.
17. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21: 2747–2761.
18. Campbell KN, Wong JS, Gupta R, Asanuma K, Sudol M, He JC et al. Yes-associated protein (YAP) promotes cell survival by inhibiting proapoptotic dendrin signaling. J Biol Chem 2013; 288: 17057–17062.
19. Schwartzman M, Reginensi A, Wong JS, Basgen JM, Meliambro K, Nicholas SB et al. Podocyte-specific deletion of Yes-associated protein causes FSGS and progressive renal failure. J Am Soc Nephrol 2015; 27: 216–226.
20. Reginensi A, Scott RP, Gregorieff A, Bagherie-Lachidan M, Chung C, Lim DS et al. Yap-and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development. PLoS Genet 2013; 9: e1003380.
21. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M et al. Role of YAP/TAZ in mechanotransduction. Nature 2011; 474: 179–183.
22. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14: 931–938.
23. Comper WD. Is the LPS-mediated proteinuria mouse model relevant to human kidney disease? Nat Med 2009; 15: 133 (author reply 133–134).
24. Lee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton) 2011; 16: 30–38.
25. Fogo AB. The targeted podocyte. J Clin Invest 2011; 121: 2142–2145.
26. Daehn I, Casalena G, Zhang T, Shi S, Fenninger F, Barasch N et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest 2014; 124: 1608–1621.
27. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008; 9: 690–701.
28. Tapon N, Hall A. Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr Opin Cell Biol 1997; 9: 86–92.
29. Ma L, Rohatgi R, Kirschner MW. The Arp2/3 complex mediates actin polymerization induced by the small GTP-binding protein Cdc42. Proc Natl Acad Sci U S A 1998; 95: 15362–15367.
30. Rohatgi R, Ma L, Miki H, Lopez M, Kirchhausen T, Takenawa T et al. The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell 1999; 97: 221–231.
31. Zugasti O, Rul W, Roux P, Peyssonnaux C, Eychene A, Franke TF et al. Raf–MEK–Erk cascade in anoikis is controlled by Rac1 and Cdc42 via Akt. Mol Cell Biol 2001; 21: 6706–6717.
32. Sinha S, Yang W. Cellular signaling for activation of Rho GTPase Cdc42. Cell Signal 2008; 20: 1927–1934.
33. Yanagida-Asanuma E, Asanuma K, Kim K, Donnelly M, Young Choi H, Hyung Chang J et al. Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:Mena signaling complexes in kidney podocytes. Am J Pathol 2007; 171: 415–427.
34. Carlier MF, Ducruix A, Pantaloni D. Signalling to actin: the Cdc42-N-WASP-Arp2/3 connection. Chem Biol 1999; 6: R235–R240.
35. Kesavan G, Sand FW, Greiner TU, Johansson JK, Kobberup S, Wu X et al. Cdc42-mediated tubulogenesis controls cell specification. Cell 2009; 139: 791–801.
36. Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol 2012; 23: 785–793.
37. Hong L, Kenney SR, Phillips GK, Simpson D, Schroeder CE, Noth J et al. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem 2013; 288: 8531–8543.
38. Zhang Y, Xia H, Ge X, Chen Q, Yuan D, Chen Q et al. CD44 acts through RhoA to regulate YAP signaling. Cellular signalling 2014; 26: 2504–2513.
39. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, Kriz W et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248–258.
40. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 2010; 160: 1577–1579.
41. Bao H, Ge Y, Peng A, Gong R. Fine-tuning of NFkappaB by glycogen synthase kinase 3beta directs the fate of glomerular podocytes upon injury. Kidney Int 2015; 87: 1176–1190.
42. Lloberas J, Celada A. p21(waf1/CIP1), a CDK inhibitor and a negative feedback system that controls macrophage activation. Eur J Immunol 2009; 39: 691–694.
43. Zhang Y, Liu J, Luan G, Wang X. Inhibition of the small GTPase Cdc42 in regulation of epileptic-seizure in rats. Neuroscience 2015; 289: 381–391.
44. Zins K, Gunawardhana S, Lucas T, Abraham D, Aharinejad S. Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity. J Transl Med 2013; 11: 295.
45. Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K et al. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant 2011; 26: 2475–2484.
46. Zhang L, Li R, Shi W, Liang X, Liu S, Ye Z et al. NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice. Br J Pharmacol 2013; 170: 426–439.
47. Si J, Ge Y, Zhuang S, Wang LJ, Chen S, Gong R. Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and-independent mechanisms. Kidney Int 2013; 83: 635–646.